# Lipfendra (enlicitide decanoate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/enlicitide-decanoate

> The FDA approved Lipfendra (enlicitide decanoate), sponsored by Merck & Co., Inc. (MRK), on July 15, 2026 for to reduce low-density lipoprotein cholesterol.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Lipfendra (enlicitide decanoate) FDA approved?

Yes. The FDA approved Lipfendra (enlicitide decanoate), sponsored by Merck & Co., Inc. (MRK), on July 15, 2026 for to reduce low-density lipoprotein cholesterol. FDA novel drug approvals: "Lipfendra | enlicitide decanoate | 7/15/2026 | To reduce low-density lipoprotein cholesterol" [Calendar and source filings](https://sec-api.dev/pdufa/enlicitide-decanoate)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/enlicitide-decanoate#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Lipfendra (enlicitide decanoate) |
| Codes | MK-0616 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | To reduce low-density lipoprotein cholesterol, Arteriosclerosis, [Hyperlipidemia](https://sec-api.dev/indications/hyperlipidemia), [Hypercholesterolemia](https://sec-api.dev/indications/hypercholesterolemia) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### July 28, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hypercholesterolemia; Familial Hypercholesterolemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05952856 (A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-06." https://clinicaltrials.gov/study/NCT05952856

### July 15, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To reduce low-density lipoprotein cholesterol.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Lipfendra | enlicitide decanoate | 7/15/2026 | To reduce low-density lipoprotein cholesterol" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
- openFDA Drugs@FDA: "NDA220848 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20260715, review_priority PRIORITY; sponsor_name MSD; product LIPFENDRA (ENLICITIDE DECANOATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220848%22

### August 6, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hypercholesterolemia; Familial Hypercholesterolemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05952856 (A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-06." https://clinicaltrials.gov/study/NCT05952856?tab=results

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hyperlipidemia; Hypercholesterolemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07821944 (A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07821944

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Hyperlipidemia; Hypercholesterolemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07821944 (A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07821944

### Oct 2028 to Jan 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hypercholesterolemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06492291 (Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06492291

### October 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Hypercholesterolemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06492291 (Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06492291

### Nov 2029 to Feb 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Arteriosclerosis; Hypercholesterolaemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06008756 (Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06008756

### November 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Arteriosclerosis; Hypercholesterolaemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06008756 (Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06008756

## Same indication

- [Praluent (alirocumab)](https://sec-api.dev/pdufa/alirocumab) (REGN)
- [LIPFENDRA (enlicitide)](https://sec-api.dev/pdufa/enlicitide) (MRK)
- [Laroprovstat](https://sec-api.dev/pdufa/laroprovstat) (AZN)

Calendar months: [November 2027](https://sec-api.dev/fda-calendar/2027-11), [October 2028](https://sec-api.dev/fda-calendar/2028-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/enlicitide-decanoate.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lipfendra (enlicitide decanoate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/enlicitide-decanoate

```bibtex
@misc{secapidev_pdufa_enlicitide_decanoate_20261116,
  title        = {Lipfendra (enlicitide decanoate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/enlicitide-decanoate}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_enlicitide_decanoate_20261116","title":"Lipfendra (enlicitide decanoate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/enlicitide-decanoate","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
